EXCALIBUR PHARMACEUTICALS Trademark

Trademark Overview

On Friday, September 20, 2019, a trademark application was filed for EXCALIBUR PHARMACEUTICALS with the United States Patent and Trademark Office. The USPTO has given the EXCALIBUR PHARMACEUTICALS trademark a serial number of 88624847. The federal status of this trademark filing is SU - NON-FINAL ACTION - MAILED as of Wednesday, May 8, 2024. This trademark is owned by Excalibur Pharmaceuticals, Inc.. The EXCALIBUR PHARMACEUTICALS trademark is filed in the Pharmaceutical Products category with the following description:

Pharmaceutical, therapeutic and biopharmaceutical agents for the treatment of fibrosis, cirrhosis, liver disease, kidney disease, dermatological conditions and diseases, autoimmune diseases, inflammatory diseases, Non-Alcoholic Fatty Liver Disease, Non-Alcoholic Steatohepatitis (NASH), and Capsular contracture; pharmaceutical, therapeutic and biopharmaceutical preparations and substances for the treatment of fibrosis, cirrhosis, liver disease, kidney disease, dermatological conditions and diseases, autoimmune diseases, inflammatory diseases, Non-Alcoholic Fatty Liver Disease, Non-Alcoholic Steatohepatitis (NASH), and Capsular contracture; none of the foregoing for or related to the treatment of male erectile dysfunction
excalibur pharmaceuticals

General Information

Serial Number88624847
Word MarkEXCALIBUR PHARMACEUTICALS
Filing DateFriday, September 20, 2019
Status807 - SU - NON-FINAL ACTION - MAILED
Status DateWednesday, May 8, 2024
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, February 9, 2021

Trademark Statements

Goods and ServicesPharmaceutical, therapeutic and biopharmaceutical agents for the treatment of fibrosis, cirrhosis, liver disease, kidney disease, dermatological conditions and diseases, autoimmune diseases, inflammatory diseases, Non-Alcoholic Fatty Liver Disease, Non-Alcoholic Steatohepatitis (NASH), and Capsular contracture; pharmaceutical, therapeutic and biopharmaceutical preparations and substances for the treatment of fibrosis, cirrhosis, liver disease, kidney disease, dermatological conditions and diseases, autoimmune diseases, inflammatory diseases, Non-Alcoholic Fatty Liver Disease, Non-Alcoholic Steatohepatitis (NASH), and Capsular contracture; none of the foregoing for or related to the treatment of male erectile dysfunction
NOT AVAILABLE"PHARMACEUTICALS"

Classification Information

International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes005, 006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateThursday, September 26, 2019
Primary Code005
First Use Anywhere DateTuesday, February 8, 2022
First Use In Commerce DateTuesday, February 8, 2022

Trademark Owner History

Party NameExcalibur Pharmaceuticals, Inc.
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressNew York, NY 10016
Party NameExcalibur Pharmaceuticals, Inc.
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressNew York, NY 10016

Trademark Events

Event DateEvent Description
Friday, December 20, 2019ASSIGNED TO EXAMINER
Thursday, September 26, 2019NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Thursday, January 2, 2020NON-FINAL ACTION WRITTEN
Thursday, January 2, 2020NON-FINAL ACTION E-MAILED
Thursday, January 2, 2020NOTIFICATION OF NON-FINAL ACTION E-MAILED
Friday, June 5, 2020TEAS RESPONSE TO OFFICE ACTION RECEIVED
Friday, June 5, 2020CORRESPONDENCE RECEIVED IN LAW OFFICE
Saturday, June 6, 2020TEAS/EMAIL CORRESPONDENCE ENTERED
Monday, June 29, 2020ASSIGNED TO LIE
Tuesday, June 30, 2020DATA MODIFICATION COMPLETED
Friday, July 10, 2020FINAL REFUSAL WRITTEN
Friday, July 10, 2020FINAL REFUSAL E-MAILED
Friday, July 10, 2020NOTIFICATION OF FINAL REFUSAL EMAILED
Wednesday, January 6, 2021TEAS REQUEST FOR RECONSIDERATION RECEIVED
Wednesday, January 6, 2021CORRESPONDENCE RECEIVED IN LAW OFFICE
Wednesday, January 6, 2021TEAS/EMAIL CORRESPONDENCE ENTERED
Thursday, January 7, 2021APPROVED FOR PUB - PRINCIPAL REGISTER
Wednesday, January 20, 2021NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Tuesday, February 9, 2021PUBLISHED FOR OPPOSITION
Tuesday, February 9, 2021OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, April 6, 2021NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Wednesday, September 29, 2021SOU TEAS EXTENSION RECEIVED
Wednesday, September 29, 2021SOU EXTENSION 1 FILED
Wednesday, September 29, 2021SOU EXTENSION 1 GRANTED
Friday, October 1, 2021NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Wednesday, April 6, 2022SOU TEAS EXTENSION RECEIVED
Wednesday, April 6, 2022SOU EXTENSION 2 FILED
Wednesday, April 6, 2022SOU EXTENSION 2 GRANTED
Friday, April 8, 2022NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Thursday, October 6, 2022SOU TEAS EXTENSION RECEIVED
Thursday, October 6, 2022SOU EXTENSION 3 FILED
Thursday, October 6, 2022SOU EXTENSION 3 GRANTED
Saturday, October 8, 2022NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Tuesday, April 4, 2023SOU TEAS EXTENSION RECEIVED
Tuesday, April 4, 2023SOU EXTENSION 4 FILED
Tuesday, April 4, 2023SOU EXTENSION 4 GRANTED
Thursday, April 6, 2023NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Monday, August 28, 2023SOU TEAS EXTENSION RECEIVED
Monday, August 28, 2023SOU EXTENSION 5 FILED
Tuesday, September 5, 2023CASE ASSIGNED TO INTENT TO USE PARALEGAL
Tuesday, September 5, 2023SOU EXTENSION 5 GRANTED
Wednesday, September 6, 2023NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Monday, April 8, 2024USE AMENDMENT FILED
Monday, April 8, 2024TEAS STATEMENT OF USE RECEIVED
Tuesday, April 16, 2024STATEMENT OF USE PROCESSING COMPLETE
Wednesday, May 8, 2024NON-FINAL ACTION E-MAILED
Wednesday, May 8, 2024NOTIFICATION OF NON-FINAL ACTION E-MAILED
Wednesday, May 8, 2024SU - NON-FINAL ACTION - WRITTEN
Thursday, August 8, 2024TEAS RESPONSE TO OFFICE ACTION RECEIVED

Related Keywords

pharmaceuticals excalibur diseases disease liver alcoholic treatment autoimmune pharmaceutical steatohepatitis contracture capsular